PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30831484-14 2019 Then, the Ser9 phosphorylation of GSK3beta can be reduced / raised by GO 6983 / LiCl, respectively. Lithium Chloride 80-84 glycogen synthase kinase 3 beta Homo sapiens 34-42 33557839-2 2021 Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 78-109 32888132-4 2020 Lithium chloride is a glycogen synthase kinase 3beta (GSK-3beta) inhibitor and exert its effects through modulation of nitric oxide pathway. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 22-52 30868765-6 2019 Combined with LiCl or MG-132 treatment, SPINK5 can inhibit GSK3beta phosphorylation and promote beta-catenin protein degradation, thus inhibit Wnt/beta-catenin signaling pathway. Lithium Chloride 14-18 glycogen synthase kinase 3 beta Homo sapiens 59-67 31935492-7 2020 Our results propose GSK3beta as new target for neuroprotection, therefore, we verified that the two GSK3beta inhibitors N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine (TC-G 24) and LiCl are neuroprotective agents in OGD and also can be used as PostC agents. Lithium Chloride 204-208 glycogen synthase kinase 3 beta Homo sapiens 20-28 31935492-7 2020 Our results propose GSK3beta as new target for neuroprotection, therefore, we verified that the two GSK3beta inhibitors N-(3-Chloro-4-methylphenyl)-5-(4-nitrophenyl)-1,3,4-oxadiazol-2-amine (TC-G 24) and LiCl are neuroprotective agents in OGD and also can be used as PostC agents. Lithium Chloride 204-208 glycogen synthase kinase 3 beta Homo sapiens 100-108 31607135-1 2020 Glycogen synthase kinase beta (GSK3beta) is considered as a promising target for lung cancer treatment and its inhibitor lithium chloride (LiCl) is widely regarded as having potent anti-proliferative and apoptosis-modulating activities. Lithium Chloride 121-137 glycogen synthase kinase 3 beta Homo sapiens 31-39 31607135-1 2020 Glycogen synthase kinase beta (GSK3beta) is considered as a promising target for lung cancer treatment and its inhibitor lithium chloride (LiCl) is widely regarded as having potent anti-proliferative and apoptosis-modulating activities. Lithium Chloride 139-143 glycogen synthase kinase 3 beta Homo sapiens 31-39 31055215-6 2019 Moreover, the negative effect of complex 1 was reversed by LiCl, a GSK3beta-specific inhibitor of the PI3K signaling pathway. Lithium Chloride 59-63 glycogen synthase kinase 3 beta Homo sapiens 67-75 30022447-6 2019 Activation of the downstream Wnt-pathway by means of heterologous beta-catenin and/or TCF-4 expression, through inhibition of GSK-3beta by LiCl treatment, or by cell stimulation with insulin-like growth factor-1 (IGF-1) resulted in increased EMN expression. Lithium Chloride 139-143 glycogen synthase kinase 3 beta Homo sapiens 126-135 30191639-8 2018 Involvement of GSK3beta was also confirmed by treatment with lithium chloride, the inducer of GSK3beta phosphorylation, or MG132, the 26S proteasomal inhibitor, which also stabilized Snail1. Lithium Chloride 61-77 glycogen synthase kinase 3 beta Homo sapiens 15-23 30834157-6 2019 Furthermore, NSCs treated with lithium chloride showed significantly enhanced beta-catenin expression and inhibited Gsk-3beta expression in a dose-dependent manner. Lithium Chloride 31-47 glycogen synthase kinase 3 beta Homo sapiens 116-125 30272331-5 2018 The aim of this study was to establish a model with which to study EMT, stemness features and cell plasticity in cancer progression and to examine the effects of incubation with lithium chloride (LiCl), a specific glycogen synthase kinase 3 beta (GSK-3beta) inhibitor, on these cellular processes. Lithium Chloride 178-194 glycogen synthase kinase 3 beta Homo sapiens 214-245 30272331-5 2018 The aim of this study was to establish a model with which to study EMT, stemness features and cell plasticity in cancer progression and to examine the effects of incubation with lithium chloride (LiCl), a specific glycogen synthase kinase 3 beta (GSK-3beta) inhibitor, on these cellular processes. Lithium Chloride 178-194 glycogen synthase kinase 3 beta Homo sapiens 247-256 30191639-8 2018 Involvement of GSK3beta was also confirmed by treatment with lithium chloride, the inducer of GSK3beta phosphorylation, or MG132, the 26S proteasomal inhibitor, which also stabilized Snail1. Lithium Chloride 61-77 glycogen synthase kinase 3 beta Homo sapiens 94-102 28871429-6 2018 Interestingly, treatment with lithium chloride, which is a well-known inhibitor of GSK3beta, partially recovered the expression of ATF4 protein, but its effect on the level of total c-Myc protein was negligible. Lithium Chloride 30-46 glycogen synthase kinase 3 beta Homo sapiens 83-91 29968965-6 2018 Furthermore, IQUB overexpression or knockdown combined with treatment of Licl or MG-132 showed that IQUB activated Akt to promote GSK3beta phosphorylation, which in turn activated Wnt/beta-catenin signaling pathway in breast cancer cells. Lithium Chloride 73-77 glycogen synthase kinase 3 beta Homo sapiens 130-138 29891461-8 2018 LiCl, an inhibitor of GSK-3beta, attenuated HG-induced ERS and significantly lowered the expression levels of GRP78 and CHOP (P<0.01). Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 22-31 30123351-5 2018 Moreover, phosphor mutants of CAP1 at the S307/S309 regulatory site had compromised rescue effects for both the invasiveness and the proliferation in CAP1-knockdown cells and GSK3beta kinase inhibitor LiCl inhibited cell phosphorylation site S307/S309 by up-regulating the expression of p53, BAK, BAD and cleaved PARP induced ROS production, decreased lung cancer cell viability, adhesion, proliferation, migration and invasion, and induction of apoptosis. Lithium Chloride 201-205 glycogen synthase kinase 3 beta Homo sapiens 175-183 30013652-9 2018 Lithium chloride (LiCl), a GSK-3beta inhibitor, prevented juglone-mediated downregulation of Snail expression and upregulation of E-cadherin. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 27-36 30013652-9 2018 Lithium chloride (LiCl), a GSK-3beta inhibitor, prevented juglone-mediated downregulation of Snail expression and upregulation of E-cadherin. Lithium Chloride 18-22 glycogen synthase kinase 3 beta Homo sapiens 27-36 29231977-8 2018 In addition, lithium chloride (LiCl), an activator of Wnt/beta-catenin signaling pathway, markedly attenuated overexpression BAK1-induced mitochondrial apoptosis by restoring the expression levels of Ser9-GSK3beta and beta-catenin. Lithium Chloride 13-29 glycogen synthase kinase 3 beta Homo sapiens 200-213 29231977-8 2018 In addition, lithium chloride (LiCl), an activator of Wnt/beta-catenin signaling pathway, markedly attenuated overexpression BAK1-induced mitochondrial apoptosis by restoring the expression levels of Ser9-GSK3beta and beta-catenin. Lithium Chloride 31-35 glycogen synthase kinase 3 beta Homo sapiens 200-213 29891449-0 2018 [Lithium chloride arrests HK-2 cell cycle in G2 phase through AKT/GSK-3beta signal pathway]. Lithium Chloride 1-17 glycogen synthase kinase 3 beta Homo sapiens 66-75 29891449-5 2018 The expressions of cyclin B1, CDK1, p-GSK-3beta, and beta-catenin increased and the expression of p-AKT decreased significantly in the cells as LiCl treatment time and concentration increased. Lithium Chloride 144-148 glycogen synthase kinase 3 beta Homo sapiens 38-47 29891449-6 2018 CONCLUSION: LiCl may cause HK-2 cell cycle arrest in G2 phase through activation of the AKT/GSK-3beta signaling pathway. Lithium Chloride 12-16 glycogen synthase kinase 3 beta Homo sapiens 92-101 29136173-9 2018 Addition of LiCl, a GSK3beta inhibitor, significantly increased osteogenic differentiation in FH-pMSCs, suggesting a relationship between the microenvironment and regulation of stem cell behaviour in ONFH. Lithium Chloride 12-16 glycogen synthase kinase 3 beta Homo sapiens 20-28 28886972-6 2018 As expected, blockage of GSK-3beta activity with a GSK-3beta inhibitor lithium chloride (LiCl) or activation of Akt signaling with an Akt agonist insulin-like growth factor-1 (IGF-1) could inhibit HQ-induced activation of GSK-3beta as well as hematotoxicity. Lithium Chloride 71-87 glycogen synthase kinase 3 beta Homo sapiens 51-60 28867214-0 2018 Lithium chloride inhibits StAR and progesterone production through GSK-3beta and ERK1/2 signaling pathways in human granulosa-lutein cells. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 67-76 28867214-6 2018 Additionally, LiCl induced the phosphorylation of GSK-3beta and ERK1/2 but not AKT or CREB. Lithium Chloride 14-18 glycogen synthase kinase 3 beta Homo sapiens 50-59 28867214-7 2018 Knockdown of endogenous GSK-3beta or inhibition of ERK1/2 partially reversed LiCl-induced down-regulation of StAR. Lithium Chloride 77-81 glycogen synthase kinase 3 beta Homo sapiens 24-33 28867214-8 2018 Furthermore, by using dual inhibition approaches, the results showed that both GSK-3beta and ERK1/2 signaling mediated the regulatory effect of LiCl on StAR expression. Lithium Chloride 144-148 glycogen synthase kinase 3 beta Homo sapiens 79-88 29531810-9 2018 Prior to phenotypic changes, lithium chloride altered Wnt signalling with elevations in AXIN2, GSK3beta phosphorylation and beta-catenin. Lithium Chloride 29-45 glycogen synthase kinase 3 beta Homo sapiens 95-103 28886972-6 2018 As expected, blockage of GSK-3beta activity with a GSK-3beta inhibitor lithium chloride (LiCl) or activation of Akt signaling with an Akt agonist insulin-like growth factor-1 (IGF-1) could inhibit HQ-induced activation of GSK-3beta as well as hematotoxicity. Lithium Chloride 71-87 glycogen synthase kinase 3 beta Homo sapiens 25-34 28886972-6 2018 As expected, blockage of GSK-3beta activity with a GSK-3beta inhibitor lithium chloride (LiCl) or activation of Akt signaling with an Akt agonist insulin-like growth factor-1 (IGF-1) could inhibit HQ-induced activation of GSK-3beta as well as hematotoxicity. Lithium Chloride 71-87 glycogen synthase kinase 3 beta Homo sapiens 51-60 28886972-6 2018 As expected, blockage of GSK-3beta activity with a GSK-3beta inhibitor lithium chloride (LiCl) or activation of Akt signaling with an Akt agonist insulin-like growth factor-1 (IGF-1) could inhibit HQ-induced activation of GSK-3beta as well as hematotoxicity. Lithium Chloride 89-93 glycogen synthase kinase 3 beta Homo sapiens 25-34 28367588-1 2017 BACKGROUND AND OBJECTIVES: Lithium chloride (LiCl) has been shown to improve the tightness of brain endothelial cell monolayers in vitro by inhibition of the GSK-3beta enzyme, activation of the Wnt/beta-catenin pathway and regulation of tight junction (TJ) protein expression. Lithium Chloride 27-43 glycogen synthase kinase 3 beta Homo sapiens 158-167 29763908-13 2018 Furthermore, treatment of Cx43-knockdown cells with lithium chloride (LiCl), a GSK-3beta inhibitor, reduced osteogenic differentiation and decreased GSK-3beta levels, as well as partially rescued levels of both total and activated beta-catenin. Lithium Chloride 52-68 glycogen synthase kinase 3 beta Homo sapiens 79-88 29763908-13 2018 Furthermore, treatment of Cx43-knockdown cells with lithium chloride (LiCl), a GSK-3beta inhibitor, reduced osteogenic differentiation and decreased GSK-3beta levels, as well as partially rescued levels of both total and activated beta-catenin. Lithium Chloride 52-68 glycogen synthase kinase 3 beta Homo sapiens 149-158 29763908-13 2018 Furthermore, treatment of Cx43-knockdown cells with lithium chloride (LiCl), a GSK-3beta inhibitor, reduced osteogenic differentiation and decreased GSK-3beta levels, as well as partially rescued levels of both total and activated beta-catenin. Lithium Chloride 70-74 glycogen synthase kinase 3 beta Homo sapiens 79-88 29763908-13 2018 Furthermore, treatment of Cx43-knockdown cells with lithium chloride (LiCl), a GSK-3beta inhibitor, reduced osteogenic differentiation and decreased GSK-3beta levels, as well as partially rescued levels of both total and activated beta-catenin. Lithium Chloride 70-74 glycogen synthase kinase 3 beta Homo sapiens 149-158 28367588-1 2017 BACKGROUND AND OBJECTIVES: Lithium chloride (LiCl) has been shown to improve the tightness of brain endothelial cell monolayers in vitro by inhibition of the GSK-3beta enzyme, activation of the Wnt/beta-catenin pathway and regulation of tight junction (TJ) protein expression. Lithium Chloride 45-49 glycogen synthase kinase 3 beta Homo sapiens 158-167 27840100-14 2017 Blockade of GSK-3beta expression by siRNA and inhibition of GSK-3beta activity by lithium chloride significantly reduced tanshinone IIA-induced AQP1 and AQP3 expression (All P<0.05). Lithium Chloride 82-98 glycogen synthase kinase 3 beta Homo sapiens 60-69 28880013-8 2017 In addition, inhibition of GSK3beta by LiCl prevented osimertinib-induced PD-L1 degradation. Lithium Chloride 39-43 glycogen synthase kinase 3 beta Homo sapiens 27-35 29039491-11 2017 The pathway activity can be modulated by LiCl at the GSK3beta-SUFU-GLI level, suggesting at least partial non-canonical activation. Lithium Chloride 41-45 glycogen synthase kinase 3 beta Homo sapiens 53-61 28943961-7 2017 Moreover, the stimulation effects of lithium chloride, a GSK3beta inhibitor, on the accumulation of beta-catenin were notably suppressed by ARHGAP10 overexpression. Lithium Chloride 37-53 glycogen synthase kinase 3 beta Homo sapiens 57-65 28911173-6 2017 Using dual inhibition approaches, our results show that LiCl initiates the hGL cellular action by inhibiting the activity of glycogen synthase kinase-3beta [GSK-3beta (phosphorylation of GSK-3beta)] and activation of extracellular signal-regulated kinase 1/2 (ERK1/2), but not by affecting protein kinase B or cAMP response element binding protein signaling. Lithium Chloride 56-60 glycogen synthase kinase 3 beta Homo sapiens 125-155 28911173-6 2017 Using dual inhibition approaches, our results show that LiCl initiates the hGL cellular action by inhibiting the activity of glycogen synthase kinase-3beta [GSK-3beta (phosphorylation of GSK-3beta)] and activation of extracellular signal-regulated kinase 1/2 (ERK1/2), but not by affecting protein kinase B or cAMP response element binding protein signaling. Lithium Chloride 56-60 glycogen synthase kinase 3 beta Homo sapiens 157-166 28911173-6 2017 Using dual inhibition approaches, our results show that LiCl initiates the hGL cellular action by inhibiting the activity of glycogen synthase kinase-3beta [GSK-3beta (phosphorylation of GSK-3beta)] and activation of extracellular signal-regulated kinase 1/2 (ERK1/2), but not by affecting protein kinase B or cAMP response element binding protein signaling. Lithium Chloride 56-60 glycogen synthase kinase 3 beta Homo sapiens 187-196 28911173-8 2017 Furthermore, knockdown of either beta-catenin or GSK-3beta reversed the LiCl-induced upregulation of COX-2 expression. Lithium Chloride 72-76 glycogen synthase kinase 3 beta Homo sapiens 49-58 28911173-9 2017 These results indicate that LiCl upregulates the expression of COX-2 and the subsequent production of PGE2 through the canonical GSK-3beta/beta-catenin signaling pathway in hGL cells. Lithium Chloride 28-32 glycogen synthase kinase 3 beta Homo sapiens 129-138 28677426-12 2017 In addition, the inhibition of beta-catenin phosphorylation by glycogen synthase kinase 3 beta inhibitor, LiCl, significantly enhanced the migration and invasion capacities in DKK1-knockdown cell lines. Lithium Chloride 106-110 glycogen synthase kinase 3 beta Homo sapiens 63-94 26996066-6 2017 Inactivation of GSK-3beta by LiCl (lithium chloride) treatment notably increased MMP-2 activity, vascular endothelial growth factor expression and EMT of MCF-7 cells. Lithium Chloride 29-33 glycogen synthase kinase 3 beta Homo sapiens 16-25 26996066-6 2017 Inactivation of GSK-3beta by LiCl (lithium chloride) treatment notably increased MMP-2 activity, vascular endothelial growth factor expression and EMT of MCF-7 cells. Lithium Chloride 35-51 glycogen synthase kinase 3 beta Homo sapiens 16-25 28123643-7 2017 We also showed that the GSK3beta inhibitor LiCl can partly disable SAHF formation through the HMGA2 overexpression in WI38 cells. Lithium Chloride 43-47 glycogen synthase kinase 3 beta Homo sapiens 24-32 29442024-7 2017 Inhibition of GSK3beta by LiCl suppressed cyclin D1 phosphorylation and downregulation by EA-AKO. Lithium Chloride 26-30 glycogen synthase kinase 3 beta Homo sapiens 14-22 28459216-5 2017 Introduction of LiCl, a glycogen synthase kinase 3beta inhibitor, rescued the Abrus agglutinin-stimulated inhibition of beta-catenin and phosphorylated glycogen synthase kinase 3beta in FaDu cell-derived orospheres confirming importance of Wnt signaling in Abrus agglutinin-mediated inhibition of stemness. Lithium Chloride 16-20 glycogen synthase kinase 3 beta Homo sapiens 24-54 28459216-5 2017 Introduction of LiCl, a glycogen synthase kinase 3beta inhibitor, rescued the Abrus agglutinin-stimulated inhibition of beta-catenin and phosphorylated glycogen synthase kinase 3beta in FaDu cell-derived orospheres confirming importance of Wnt signaling in Abrus agglutinin-mediated inhibition of stemness. Lithium Chloride 16-20 glycogen synthase kinase 3 beta Homo sapiens 152-182 28575066-7 2017 In the course of this, LiCl induced inhibitory glycogen synthase kinase-3beta (GSK-3beta) serine 9 phosphorylation, whereas glioma associated oncogene family 1 (GLI1) protein expression was particularly reduced by combined ATO and LiCl treatment in RD and RH-30 cell lines, showing high rates of apoptotic cell death. Lithium Chloride 23-27 glycogen synthase kinase 3 beta Homo sapiens 47-77 28575066-7 2017 In the course of this, LiCl induced inhibitory glycogen synthase kinase-3beta (GSK-3beta) serine 9 phosphorylation, whereas glioma associated oncogene family 1 (GLI1) protein expression was particularly reduced by combined ATO and LiCl treatment in RD and RH-30 cell lines, showing high rates of apoptotic cell death. Lithium Chloride 23-27 glycogen synthase kinase 3 beta Homo sapiens 79-88 27618015-13 2016 However, the abnormal rise of apoptosis at 30 mM of LiCl concentration implies that it might be the reduction of GSK3beta that increased cell apoptosis. Lithium Chloride 52-56 glycogen synthase kinase 3 beta Homo sapiens 113-121 27908414-3 2017 We used an inducible canonical wnt signaling system that utilizes LiCl (GSK-3beta inhibitor). Lithium Chloride 66-70 glycogen synthase kinase 3 beta Homo sapiens 72-81 27490211-13 2016 Anti-GSK3 beta, pGSK3 beta, Bcl-2, Akt-1, p-Akt1 protein levels were observed with cells exposed to Tideglusib and Lithium chloride. Lithium Chloride 115-131 glycogen synthase kinase 3 beta Homo sapiens 5-14 27470348-10 2016 LiCl, a potent GSK-3beta inhibitor, can obviously reverse EGF induced up regulation of p65 phosphorylation. Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 15-24 26935904-14 2016 Decreased VEGFR-2 caused by ROS was ameliorated by beta-TrCP siRNA, proteasome inhibitor MG132 and GSK-3beta activity inhibitor (lithium chloride and SB216763). Lithium Chloride 129-145 glycogen synthase kinase 3 beta Homo sapiens 99-108 26252009-9 2015 The changes in beta-catenin levels in response to embelin were blocked by lithium chloride, a GSK-3 inhibitor, indicating that embelin may decrease beta-catenin expression via GSK-3beta activation. Lithium Chloride 74-90 glycogen synthase kinase 3 beta Homo sapiens 176-185 26631736-7 2016 Lithium chloride inhibition of GSK-3beta increased nuclear beta-catenin content and normalized nuclear PPAR-gamma in Ob-MSCs. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 31-40 26926171-13 2016 Inhibition of GSK3beta by LiCl suppressed cyclin D1 phosphorylation and downregulation by MRB. Lithium Chloride 26-30 glycogen synthase kinase 3 beta Homo sapiens 14-22 26674355-5 2015 Lithium chloride (LiCl) and short interfering RNA (siRNA)-mediated inhibition of GSK-3beta significantly enhanced the ability of hyperoside to protect L02 liver cells from H2O2-induced oxidative damage, leading to increased cell survival shown by the maintenance of cell membrane integrity and elevated levels of glutathione (GSH), one of the endogenous antioxidant biomarkers. Lithium Chloride 18-22 glycogen synthase kinase 3 beta Homo sapiens 81-90 26560046-8 2015 Meanwhile, LiCl increased GSK3beta transcript levels and the proliferation of CaSki cells in a HPV16-dependent manner. Lithium Chloride 11-15 glycogen synthase kinase 3 beta Homo sapiens 26-34 26516309-0 2015 Lithium Chloride Promotes Apoptosis in Human Leukemia NB4 Cells by Inhibiting Glycogen Synthase Kinase-3 Beta. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 78-109 26516309-7 2015 Moreover, LiCl significantly increased the level of Ser9-phosphorylated glycogen synthase kinase 3beta(p-GSK-3beta), and decreased the level of Akt1 protein in a dose-dependent manner. Lithium Chloride 10-14 glycogen synthase kinase 3 beta Homo sapiens 105-114 25840567-9 2016 Inhibition of GSK3beta by LiCl led to increased levels of beta-catenin, LEF-1, cyclin D1, and CXCR-4 expression. Lithium Chloride 26-30 glycogen synthase kinase 3 beta Homo sapiens 14-22 26385428-5 2015 We show that inhibition of GSK3beta with lithium chloride enhances Gli3 processing into its repressor form, consequently downregulating Hh-Gli signaling, reducing cell proliferation and inducing cell death. Lithium Chloride 41-57 glycogen synthase kinase 3 beta Homo sapiens 27-35 26385428-6 2015 Analysis of the molecular mechanisms revealed that lithium chloride enhances Gli3-SuFu-GSK3beta complex formation leading to more efficient Gli3 cleavage and Hh-Gli signaling downregulation. Lithium Chloride 51-67 glycogen synthase kinase 3 beta Homo sapiens 87-95 26236947-8 2015 Moreover, AMPK-induced GSK3beta and SIRT1 activities were found to be responsible for inhibiting c-Myc-mediated upregulation of MTDH, as LiCl (an inhibitor of GSK3beta) and EX-527 (an inhibitor of SIRT1) reversed AICAR-mediated downregulation of c-Myc and MTDH expressions. Lithium Chloride 137-141 glycogen synthase kinase 3 beta Homo sapiens 23-31 26236947-8 2015 Moreover, AMPK-induced GSK3beta and SIRT1 activities were found to be responsible for inhibiting c-Myc-mediated upregulation of MTDH, as LiCl (an inhibitor of GSK3beta) and EX-527 (an inhibitor of SIRT1) reversed AICAR-mediated downregulation of c-Myc and MTDH expressions. Lithium Chloride 137-141 glycogen synthase kinase 3 beta Homo sapiens 159-167 25738332-10 2015 Following differentiation with the glycogen synthase kinase 3beta (GSK3beta) inhibitor LiCl, the cells began to express E-cadherin and, at once, Twist1 and Snail expression was strongly downregulated, suggesting a MET-reverting process. Lithium Chloride 87-91 glycogen synthase kinase 3 beta Homo sapiens 35-65 26087957-10 2015 Furthermore, the effect of MK-2206 on Mcl-1 downregulation was abolished by GSK3beta inhibitor, lithium chloride and proteasome inhibitor, MG-132, suggesting that MK-2206 acted through a GSK3beta-mediated, proteasome-dependent protein degradation. Lithium Chloride 96-112 glycogen synthase kinase 3 beta Homo sapiens 187-195 25738332-10 2015 Following differentiation with the glycogen synthase kinase 3beta (GSK3beta) inhibitor LiCl, the cells began to express E-cadherin and, at once, Twist1 and Snail expression was strongly downregulated, suggesting a MET-reverting process. Lithium Chloride 87-91 glycogen synthase kinase 3 beta Homo sapiens 67-75 25738332-13 2015 Our observation indicates that LiCl, a GSK3beta inhibitor, induces MET in vitro, suggesting that LiCl and GSK3beta could represent, respectively, interesting drug, and target for CRC therapy. Lithium Chloride 31-35 glycogen synthase kinase 3 beta Homo sapiens 39-47 25738332-13 2015 Our observation indicates that LiCl, a GSK3beta inhibitor, induces MET in vitro, suggesting that LiCl and GSK3beta could represent, respectively, interesting drug, and target for CRC therapy. Lithium Chloride 31-35 glycogen synthase kinase 3 beta Homo sapiens 106-114 25187518-10 2014 The oxidative stress-induced mitochondrial translocation of GSK-3beta was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3beta inhibitor. Lithium Chloride 141-157 glycogen synthase kinase 3 beta Homo sapiens 60-69 24760594-6 2015 We found that LiCl mobilizes the alpha-tubulin N-acetyltransferase 1 (alphaTAT1) in the signaling pathway mediating GSK-3beta and adenylate cyclase III. Lithium Chloride 14-18 glycogen synthase kinase 3 beta Homo sapiens 116-125 24760594-7 2015 In conclusion, our results suggested that LiCl treatments activate alphaTAT1 by the inhibition of GSK-3beta and promote the alpha-tubulin acetylation, and then elongate the primary cilia. Lithium Chloride 42-46 glycogen synthase kinase 3 beta Homo sapiens 98-107 25187518-10 2014 The oxidative stress-induced mitochondrial translocation of GSK-3beta was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3beta inhibitor. Lithium Chloride 141-157 glycogen synthase kinase 3 beta Homo sapiens 168-177 25187518-10 2014 The oxidative stress-induced mitochondrial translocation of GSK-3beta was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3beta inhibitor. Lithium Chloride 159-163 glycogen synthase kinase 3 beta Homo sapiens 60-69 25187518-10 2014 The oxidative stress-induced mitochondrial translocation of GSK-3beta was associated with an increase in cell death, which was suppressed by lithium chloride (LiCl), a GSK-3beta inhibitor. Lithium Chloride 159-163 glycogen synthase kinase 3 beta Homo sapiens 168-177 24571487-9 2014 These findings were recapitulated by treatment with the GSK-3beta inhibitor, LiCl. Lithium Chloride 77-81 glycogen synthase kinase 3 beta Homo sapiens 56-65 24975844-6 2014 Blocking Glycogen Synthase Kinase (GSK3beta) activity by lithium chloride or Dvl gene overexpression restored beta-catenin expression. Lithium Chloride 57-73 glycogen synthase kinase 3 beta Homo sapiens 35-43 24894198-7 2014 Moreover, GSK3beta deletion or GSK3beta inhibition by LiCl treatment resulted in increased p21 expression and reduced Sox2 expression in osteosarcoma cells. Lithium Chloride 54-58 glycogen synthase kinase 3 beta Homo sapiens 10-18 24894198-7 2014 Moreover, GSK3beta deletion or GSK3beta inhibition by LiCl treatment resulted in increased p21 expression and reduced Sox2 expression in osteosarcoma cells. Lithium Chloride 54-58 glycogen synthase kinase 3 beta Homo sapiens 31-39 25148525-7 2014 Inhibition of GSK3beta with LiCl (the inhibitor of GSK3beta) increased the expression of Snail and beta-catenin in cultured kidney epithelial cells. Lithium Chloride 28-32 glycogen synthase kinase 3 beta Homo sapiens 14-22 25148525-7 2014 Inhibition of GSK3beta with LiCl (the inhibitor of GSK3beta) increased the expression of Snail and beta-catenin in cultured kidney epithelial cells. Lithium Chloride 28-32 glycogen synthase kinase 3 beta Homo sapiens 51-59 24549719-0 2014 Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3beta. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 122-131 24549719-6 2014 GSK-3beta could be phosphorylated at Ser9 and its activity was inhibited when C6 glioma cells were treated by lithium chloride. Lithium Chloride 110-126 glycogen synthase kinase 3 beta Homo sapiens 0-9 24610780-8 2014 Our results show that the GSK3beta kinase inhibitors LiCl, SB 216763, and SB 415286 prevent copper-responsive APP trafficking. Lithium Chloride 53-57 glycogen synthase kinase 3 beta Homo sapiens 26-34 24132507-7 2014 However, inhibition of GSK-3beta activity with lithium chloride treatment or knockdown of GSK-3beta expression with shRNA suppressed sodium palmitate-induced lipoapoptosis in L02 and HepG2 cells. Lithium Chloride 47-63 glycogen synthase kinase 3 beta Homo sapiens 23-32 24448371-13 2014 GSK-3beta/beta-catenin/Mre11 pathway might be the connection between LiCl treatment and the decreased DNA repair in T47D cells. Lithium Chloride 69-73 glycogen synthase kinase 3 beta Homo sapiens 0-9 24025791-0 2013 RNAi screening identifies GSK3beta as a regulator of DRP1 and the neuroprotection of lithium chloride against elevated pressure involved in downregulation of DRP1. Lithium Chloride 85-101 glycogen synthase kinase 3 beta Homo sapiens 26-34 25002914-0 2014 Lithium chloride suppresses colorectal cancer cell survival and proliferation through ROS/GSK-3beta/NF-kappaB signaling pathway. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 90-99 23872260-7 2013 Blocking GSK3beta/beta-catenin pathway was required for wogonin-induced proliferation inhibition and terminal differentiation by using canonical activator lithium chloride (LiCl) and inhibitor dickkopf-1 (Dkk1). Lithium Chloride 155-171 glycogen synthase kinase 3 beta Homo sapiens 9-17 23872260-7 2013 Blocking GSK3beta/beta-catenin pathway was required for wogonin-induced proliferation inhibition and terminal differentiation by using canonical activator lithium chloride (LiCl) and inhibitor dickkopf-1 (Dkk1). Lithium Chloride 173-177 glycogen synthase kinase 3 beta Homo sapiens 9-17 23685991-8 2014 Expression of constitutive active GSK3beta(S9A) represses LiCl-mediated enhancement of IRF3 transactivation activity. Lithium Chloride 58-62 glycogen synthase kinase 3 beta Homo sapiens 34-42 23871716-0 2013 Inhibition of glycogen synthase kinase-3beta by lithium chloride suppresses 6-hydroxydopamine-induced inflammatory response in primary cultured astrocytes. Lithium Chloride 48-64 glycogen synthase kinase 3 beta Homo sapiens 14-44 23871716-9 2013 Besides, GSK-3beta inhibitor LiCl and SB415286 inhibited the GSK-3beta/NF-kappaB signaling pathway, leading to the reduction of proinflammatory molecules in 6-OHDA-activated astrocytes. Lithium Chloride 29-33 glycogen synthase kinase 3 beta Homo sapiens 9-18 23871716-9 2013 Besides, GSK-3beta inhibitor LiCl and SB415286 inhibited the GSK-3beta/NF-kappaB signaling pathway, leading to the reduction of proinflammatory molecules in 6-OHDA-activated astrocytes. Lithium Chloride 29-33 glycogen synthase kinase 3 beta Homo sapiens 61-70 23871716-10 2013 These results confirmed that GSK-3beta inhibitor LiCl and SB415286 provide protection against neuroinflammation in 6-OHDA-treated astrocytes. Lithium Chloride 49-53 glycogen synthase kinase 3 beta Homo sapiens 29-38 24025791-6 2013 Use of the pharmacological inhibitor of GSK3beta inhibitor, lithium chloride (LiCl), confirmed this result. Lithium Chloride 60-76 glycogen synthase kinase 3 beta Homo sapiens 40-48 24025791-6 2013 Use of the pharmacological inhibitor of GSK3beta inhibitor, lithium chloride (LiCl), confirmed this result. Lithium Chloride 78-82 glycogen synthase kinase 3 beta Homo sapiens 40-48 25206585-5 2013 The level of active Caspase-3 and the ratio of Bax/Bcl-2 in hippocampal neurons treated with TLR4 antibody or the GSK-3beta inhibitor, LiCl, creased before intervention with lipopolysaccharide, but increased after treatment with the AKT hibitor, LY294002. Lithium Chloride 135-139 glycogen synthase kinase 3 beta Homo sapiens 114-123 23941783-5 2013 Inhibition of GSK3beta by either lithium chloride (LiCl) or specific GSK3beta inhibitor VIII showed cytostatic and cytotoxic effects on multiple endometrial cancer cell lines, with little effect on the immortalized normal endometrial cell line. Lithium Chloride 33-49 glycogen synthase kinase 3 beta Homo sapiens 14-22 23954827-6 2013 After treatment with lithium chloride (LiCl), the protein expression of phospho GSK-3beta and beta-catenin was increased in each group compared to the corresponding group without LiCl. Lithium Chloride 21-37 glycogen synthase kinase 3 beta Homo sapiens 80-89 23954827-6 2013 After treatment with lithium chloride (LiCl), the protein expression of phospho GSK-3beta and beta-catenin was increased in each group compared to the corresponding group without LiCl. Lithium Chloride 39-43 glycogen synthase kinase 3 beta Homo sapiens 80-89 23954827-6 2013 After treatment with lithium chloride (LiCl), the protein expression of phospho GSK-3beta and beta-catenin was increased in each group compared to the corresponding group without LiCl. Lithium Chloride 179-183 glycogen synthase kinase 3 beta Homo sapiens 80-89 23494401-5 2013 Inhibition of GSK-3beta with LiCl in Dianeal and Extraneal -treated cells dose-dependently decreased cell damage and death rate and was paralleled by higher HSF-1 activation and Hsp72 expression. Lithium Chloride 29-33 glycogen synthase kinase 3 beta Homo sapiens 14-23 23494401-7 2013 Inhibition of GSK-3beta with LiCl ameliorated cell injury and improved HSR upon PDF exposure. Lithium Chloride 29-33 glycogen synthase kinase 3 beta Homo sapiens 14-23 23673211-12 2013 Furthermore, phosphorylation of GSK-3beta at serine 9 by LiCl and transient interference of GSK-3beta by siRNA increased beta-catenin and survivin protein expression in A549/DDP cells. Lithium Chloride 57-61 glycogen synthase kinase 3 beta Homo sapiens 32-41 23941783-5 2013 Inhibition of GSK3beta by either lithium chloride (LiCl) or specific GSK3beta inhibitor VIII showed cytostatic and cytotoxic effects on multiple endometrial cancer cell lines, with little effect on the immortalized normal endometrial cell line. Lithium Chloride 51-55 glycogen synthase kinase 3 beta Homo sapiens 14-22 23815230-4 2013 Using the scratch wound assay and a modified Boyden chamber, we found that LY294002, a selective phosphatidylinositol 3-kinase inhibitor, and LiCl, a selective GSK3beta inhibitor, abolished LGI3-induced cell migration. Lithium Chloride 142-146 glycogen synthase kinase 3 beta Homo sapiens 160-168 23846217-11 2013 Pretreatment of LiCL, an inhibitor of GSK3beta, could significantly ameliorate apoptosis induced by celastrol. Lithium Chloride 16-20 glycogen synthase kinase 3 beta Homo sapiens 38-46 23376468-5 2013 Inhibition of GSK3beta by either phosphorylation by AKT or lithium chloride resulted in activation of pyruvate dehydrogenase, i.e., a decrease in its phosphorylated form. Lithium Chloride 59-75 glycogen synthase kinase 3 beta Homo sapiens 14-22 23449446-6 2013 In this study, we investigated beta-catenin and NF-kappaB signaling through regulation of glycogen synthase kinase 3beta activity (GSK-3beta, which modulates beta-catenin and NF-kappaB signaling) using a specific inhibitor LiCl and a phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002. Lithium Chloride 223-227 glycogen synthase kinase 3 beta Homo sapiens 90-120 23378009-8 2013 Collectively, these findings indicated that LiCl sensitized A549 cells to TRAIL-induced apoptosis through caspases-dependent apoptotic pathway via death receptors signaling and G2/M arrest induced by inhibition of JNK activation, but independent of GSK3beta. Lithium Chloride 44-48 glycogen synthase kinase 3 beta Homo sapiens 249-257 23449446-6 2013 In this study, we investigated beta-catenin and NF-kappaB signaling through regulation of glycogen synthase kinase 3beta activity (GSK-3beta, which modulates beta-catenin and NF-kappaB signaling) using a specific inhibitor LiCl and a phosphatidylinositol 3-kinase (PI3K) inhibitor LY 294002. Lithium Chloride 223-227 glycogen synthase kinase 3 beta Homo sapiens 131-140 23054864-7 2012 The results showed breast cancer cells respond in a diverse manner to LiCl, i.e., at lower concentrations (1, 5, and 10 mM), LiCl induces cell survival by inhibiting apoptosis through regulation of GSK-3beta, caspase-2, Bax, and cleaved caspase-7 and by activating anti-apoptotic proteins (Akt, beta-catenin, Bcl-2, and cyclin D1). Lithium Chloride 70-74 glycogen synthase kinase 3 beta Homo sapiens 198-207 23223575-5 2013 In the presence of quercetin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiCl restores calcium accumulation, confirming that quercetin mechanism of action hinges on inhibition of the beta-catenin pathway. Lithium Chloride 122-126 glycogen synthase kinase 3 beta Homo sapiens 69-99 23223575-5 2013 In the presence of quercetin, reactivation of beta-catenin using the glycogen synthase kinase-3beta (GSK-3beta) inhibitor LiCl restores calcium accumulation, confirming that quercetin mechanism of action hinges on inhibition of the beta-catenin pathway. Lithium Chloride 122-126 glycogen synthase kinase 3 beta Homo sapiens 101-110 23735868-14 2013 Moreover, pretreatment with NaHS blunted the stimulation of SLE lymphocyte proliferation by GSK3beta inhibitor lithium chloride. Lithium Chloride 111-127 glycogen synthase kinase 3 beta Homo sapiens 92-100 23123500-6 2013 Analogously, pre-treatment with LiCl, which induced phosphorylation of GSK3beta at Ser9, increased Wnt5a-induced cell migration. Lithium Chloride 32-36 glycogen synthase kinase 3 beta Homo sapiens 71-79 23357875-5 2013 Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation. Lithium Chloride 107-111 glycogen synthase kinase 3 beta Homo sapiens 52-82 23357875-5 2013 Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation. Lithium Chloride 107-111 glycogen synthase kinase 3 beta Homo sapiens 84-93 23357875-5 2013 Pretreatment with the proteasome inhibitor MG132 or glycogen synthase kinase-3beta (GSK-3beta) inhibitors (LiCl and SB216763) attenuated the effect of DIF-1, suggesting that DIF-1 induced c-Myc protein degradation through GSK-3beta activation. Lithium Chloride 107-111 glycogen synthase kinase 3 beta Homo sapiens 222-231 23054864-2 2012 Lithium chloride (LiCl) is a selective inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that regulates many cellular processes, in addition to its role in the regulation of glycogen synthase. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 84-93 23054864-2 2012 Lithium chloride (LiCl) is a selective inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that regulates many cellular processes, in addition to its role in the regulation of glycogen synthase. Lithium Chloride 18-22 glycogen synthase kinase 3 beta Homo sapiens 84-93 23054864-7 2012 The results showed breast cancer cells respond in a diverse manner to LiCl, i.e., at lower concentrations (1, 5, and 10 mM), LiCl induces cell survival by inhibiting apoptosis through regulation of GSK-3beta, caspase-2, Bax, and cleaved caspase-7 and by activating anti-apoptotic proteins (Akt, beta-catenin, Bcl-2, and cyclin D1). Lithium Chloride 125-129 glycogen synthase kinase 3 beta Homo sapiens 198-207 22999562-6 2012 LiCl treatment significantly affected cell morphology of U87MG and U87MG.Delta2-7 cells, while also increasing levels of phospho-GSK-3beta in a dose-dependent manner. Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 129-138 23248400-2 2012 This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs. Lithium Chloride 49-65 glycogen synthase kinase 3 beta Homo sapiens 108-117 23248400-2 2012 This study sought to determine the usefulness of lithium chloride (LiCl) as a highly selective inhibitor of GSK-3beta to increase the sensitivity of LNCap cells to doxorubicin (Dox), etoposide (Eto), and vinblastine (Vin) drugs. Lithium Chloride 67-71 glycogen synthase kinase 3 beta Homo sapiens 108-117 22740511-11 2012 Moreover, LiCl and SB216763, inhibitors of GSK-3beta augmented cell migration as well as fascin-1 mRNA expression. Lithium Chloride 10-14 glycogen synthase kinase 3 beta Homo sapiens 43-52 22999562-9 2012 We have shown in this study that GSK-3beta regulation by phosphorylation is important for cell morphology and growth, and that LiCl enhances growth of U87MG and U87MG.Delta2-7 cells by inhibiting GSK-3beta through its phosphorylation, whereas AktX reduces growth via activation of GSK-3beta by inhibiting Akt"s kinase activity. Lithium Chloride 127-131 glycogen synthase kinase 3 beta Homo sapiens 196-205 22999562-9 2012 We have shown in this study that GSK-3beta regulation by phosphorylation is important for cell morphology and growth, and that LiCl enhances growth of U87MG and U87MG.Delta2-7 cells by inhibiting GSK-3beta through its phosphorylation, whereas AktX reduces growth via activation of GSK-3beta by inhibiting Akt"s kinase activity. Lithium Chloride 127-131 glycogen synthase kinase 3 beta Homo sapiens 196-205 23408470-1 2012 Hormone-independent prostate cancer cell lines are resistant to antineoplastic drugs, this study sought to determine the usefulness of lithium chloride as an inhibitor of glycogen synthase kinase-3beta to increase the cytotoxic effect of doxorubicin, etoposide or vinblastine antineoplastic drugs on DU145 cells. Lithium Chloride 135-151 glycogen synthase kinase 3 beta Homo sapiens 171-201 22872488-3 2012 Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway. Lithium Chloride 68-84 glycogen synthase kinase 3 beta Homo sapiens 0-30 22872488-3 2012 Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway. Lithium Chloride 68-84 glycogen synthase kinase 3 beta Homo sapiens 32-41 22872488-3 2012 Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway. Lithium Chloride 86-90 glycogen synthase kinase 3 beta Homo sapiens 0-30 22872488-3 2012 Glycogen synthase kinase 3beta (GSK-3beta) inhibitors, SB216763 and lithium chloride (LiCl), were used to activate WNT/beta-catenin-signaling pathway. Lithium Chloride 86-90 glycogen synthase kinase 3 beta Homo sapiens 32-41 22964364-2 2012 Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 72-102 22964364-2 2012 Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 104-113 22964364-2 2012 Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis. Lithium Chloride 18-22 glycogen synthase kinase 3 beta Homo sapiens 72-102 22964364-2 2012 Lithium chloride (LiCl) has been considered to be a potent inhibitor of glycogen synthase kinase-3beta (GSK-3beta), a serine/threonine kinase that is involved in the control of cell proliferation, differentiation, and apoptosis. Lithium Chloride 18-22 glycogen synthase kinase 3 beta Homo sapiens 104-113 22820424-9 2012 When cells were pre-treated with LiCl, the inhibitor of GSK-3beta, the decrease of cyclin D1 was blocked and the reduction of pRb was recovered. Lithium Chloride 33-37 glycogen synthase kinase 3 beta Homo sapiens 56-65 21410737-9 2012 In addition, the GSK3beta inhibitor lithium chloride sensitizes prostate cancer cells to TZDs cytotoxicity. Lithium Chloride 36-52 glycogen synthase kinase 3 beta Homo sapiens 17-25 22262180-0 2012 GSK3beta regulates Bcl2L12 and Bcl2L12A anti-apoptosis signaling in glioblastoma and is inhibited by LiCl. Lithium Chloride 101-105 glycogen synthase kinase 3 beta Homo sapiens 0-8 21678465-0 2011 Effects of a glycogen synthase kinase-3beta inhibitor (LiCl) on c-myc protein in intervertebral disc cells. Lithium Chloride 55-59 glycogen synthase kinase 3 beta Homo sapiens 13-43 22615875-7 2012 In addition, lithium chloride-mediated inhibition of GSK3beta also resulted in increase in MENA mRNA levels. Lithium Chloride 13-29 glycogen synthase kinase 3 beta Homo sapiens 53-61 21952626-7 2011 Pharmacological inhibition of GSK3beta by lithium chloride treatment mimicked effects of Cdc42 in promotion of PARP cleavage and/or apoptosis. Lithium Chloride 42-58 glycogen synthase kinase 3 beta Homo sapiens 30-38 22506014-6 2012 VPA analogs and other GSK3beta inhibitors that activate the Wnt/beta-catenin pathway such as 4-phenyl butyric acid, LiCl, and BeCl(2) also exhibited hair growth-promoting activities in vivo. Lithium Chloride 116-120 glycogen synthase kinase 3 beta Homo sapiens 22-30 21207227-8 2011 Dysregulation of GSK-3beta caused cell apoptosis was confirmed by pharmacological inhibitors (lithium chloroid, LiCl, and 6-bro-moindirubin-3-oxime, BIO). Lithium Chloride 112-116 glycogen synthase kinase 3 beta Homo sapiens 17-26 21435461-5 2011 Further inhibition of GSK-3beta with lithium chloride, combined with glucose shortage, caused specific activation of AMP-activated protein kinase and significant suppression of proliferation in transformed but not normal cells. Lithium Chloride 37-53 glycogen synthase kinase 3 beta Homo sapiens 22-31 21360572-0 2011 Lithium chloride and staurosporine potentiate the accumulation of phosphorylated glycogen synthase kinase 3beta/Tyr216, resulting in glycogen synthase kinase 3beta activation in SH-SY5Y human neuroblastoma cell lines. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 81-111 21360572-0 2011 Lithium chloride and staurosporine potentiate the accumulation of phosphorylated glycogen synthase kinase 3beta/Tyr216, resulting in glycogen synthase kinase 3beta activation in SH-SY5Y human neuroblastoma cell lines. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 133-163 21360572-4 2011 Lithium chloride (LiCl) is usually described to increase pGSK3betaSer9 through the PI3K/Akt pathway, resulting in GSK3beta inhibition. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 58-66 21360572-4 2011 Lithium chloride (LiCl) is usually described to increase pGSK3betaSer9 through the PI3K/Akt pathway, resulting in GSK3beta inhibition. Lithium Chloride 18-22 glycogen synthase kinase 3 beta Homo sapiens 58-66 21360572-5 2011 The purpose of this study is to demonstrate that in some cases LiCl is also able to increase pGSK3betaTyr216, resulting in GSK3beta activation. Lithium Chloride 63-67 glycogen synthase kinase 3 beta Homo sapiens 94-102 21278055-7 2011 ATO, as well as LiCl (GSK-3beta inhibitor), could induce GSK-3beta(Ser9) phosphorylation and p21 expression in a time- and dose-dependent manner. Lithium Chloride 16-20 glycogen synthase kinase 3 beta Homo sapiens 22-31 21278055-7 2011 ATO, as well as LiCl (GSK-3beta inhibitor), could induce GSK-3beta(Ser9) phosphorylation and p21 expression in a time- and dose-dependent manner. Lithium Chloride 16-20 glycogen synthase kinase 3 beta Homo sapiens 57-66 21518487-6 2011 Compared with results of Western blot before treatment, expression of inactivated GSK-3beta, beta-catenin and Cyclin-D1 down-regulated in a dose-dependent manner after treatment with sorafenib, this same changes were observed after up-regulation of inactivated GSK-3beta by LiCl (p < 0.05). Lithium Chloride 274-278 glycogen synthase kinase 3 beta Homo sapiens 82-91 20672290-9 2011 The enhanced CD86 expression by LiCl involves the PI3K/AKT and GSK-3beta pathway. Lithium Chloride 32-36 glycogen synthase kinase 3 beta Homo sapiens 63-72 21239435-7 2011 In addition, lithium chloride, which increases GSK3beta phosphorylation and the nuclear translocation of beta-catenin, increased MT1-MMP levels in these ovarian cancer cells. Lithium Chloride 13-29 glycogen synthase kinase 3 beta Homo sapiens 47-55 20683916-5 2011 We found that GSK3beta activation could promote HF-LPLI-induced apoptosis, which could be prevented by lithium chloride (a selective inhibitor of GSK3beta) exposure or by GSK3beta-KD (a dominant-negative GSK3beta) overexpression. Lithium Chloride 103-119 glycogen synthase kinase 3 beta Homo sapiens 14-22 20683916-5 2011 We found that GSK3beta activation could promote HF-LPLI-induced apoptosis, which could be prevented by lithium chloride (a selective inhibitor of GSK3beta) exposure or by GSK3beta-KD (a dominant-negative GSK3beta) overexpression. Lithium Chloride 103-119 glycogen synthase kinase 3 beta Homo sapiens 146-154 20683916-5 2011 We found that GSK3beta activation could promote HF-LPLI-induced apoptosis, which could be prevented by lithium chloride (a selective inhibitor of GSK3beta) exposure or by GSK3beta-KD (a dominant-negative GSK3beta) overexpression. Lithium Chloride 103-119 glycogen synthase kinase 3 beta Homo sapiens 146-154 20926980-5 2011 Incubation of septic muscle with LiCl completely reversed the increased GSK-3[beta] activity and decreased proteolysis to basal nonseptic values, but only partially reduced proteosome activity and did not diminish atrogene expression. Lithium Chloride 33-37 glycogen synthase kinase 3 beta Homo sapiens 72-82 20672290-11 2011 The effect of LiCl on IL-6/IL-8/IL-10 secretion in iDC is mediated through inhibition of GSK-3beta. Lithium Chloride 14-18 glycogen synthase kinase 3 beta Homo sapiens 89-98 20672290-12 2011 We have also demonstrated that PPARgamma is downstream of GSK-3beta and is responsible for the LiCl-mediated modulation of CD86/83 and CD1 expression, but not IL-6/8/10 secretion. Lithium Chloride 95-99 glycogen synthase kinase 3 beta Homo sapiens 58-67 22069492-9 2011 The inhibition of Akt by SH6 and GSK3beta by lithium chloride (LiCl) could respectively induce and inhibit the STS-mediated e-lam formation, cell migration and STC1 gene expression. Lithium Chloride 45-61 glycogen synthase kinase 3 beta Homo sapiens 33-41 22069492-9 2011 The inhibition of Akt by SH6 and GSK3beta by lithium chloride (LiCl) could respectively induce and inhibit the STS-mediated e-lam formation, cell migration and STC1 gene expression. Lithium Chloride 63-67 glycogen synthase kinase 3 beta Homo sapiens 33-41 20448354-3 2010 The expression of p-GSK-3beta and total GSK-3beta in HMPC was detected by Western blot after incubation with different concentrations (0, 5, 10, 20, and 40 mmol/L)of LiCl at different time points (0, 1, 3, 6, and 12 h). Lithium Chloride 166-170 glycogen synthase kinase 3 beta Homo sapiens 20-29 20704706-4 2010 In addition, gastric cancer cells were cultured and treated with a GSK-3beta inhibitor lithium chloride (LiCl) for immunoblot analysis. Lithium Chloride 87-103 glycogen synthase kinase 3 beta Homo sapiens 67-76 20704706-4 2010 In addition, gastric cancer cells were cultured and treated with a GSK-3beta inhibitor lithium chloride (LiCl) for immunoblot analysis. Lithium Chloride 105-109 glycogen synthase kinase 3 beta Homo sapiens 67-76 20031160-9 2010 RESULTS: A dose-dependent increase in phosphorylation of GSK-3beta was observed after treatment with both ZM336372 and LiCl. Lithium Chloride 119-123 glycogen synthase kinase 3 beta Homo sapiens 57-66 20561505-6 2010 Imaging of mice tumor xenograft generated with BGCR-expressing SW620 cells following treatment with LiCl showed unique oscillations in GSK3beta activity that were corroborated by phosphorylated GSK3beta immunoblotting. Lithium Chloride 100-104 glycogen synthase kinase 3 beta Homo sapiens 135-143 20561505-6 2010 Imaging of mice tumor xenograft generated with BGCR-expressing SW620 cells following treatment with LiCl showed unique oscillations in GSK3beta activity that were corroborated by phosphorylated GSK3beta immunoblotting. Lithium Chloride 100-104 glycogen synthase kinase 3 beta Homo sapiens 194-202 20015942-9 2010 HG and lithium chloride (GSK-3beta inhibitor) blocked Snail1 and beta-catenin activation. Lithium Chloride 7-23 glycogen synthase kinase 3 beta Homo sapiens 25-34 20448354-3 2010 The expression of p-GSK-3beta and total GSK-3beta in HMPC was detected by Western blot after incubation with different concentrations (0, 5, 10, 20, and 40 mmol/L)of LiCl at different time points (0, 1, 3, 6, and 12 h). Lithium Chloride 166-170 glycogen synthase kinase 3 beta Homo sapiens 40-49 20448354-6 2010 RESULTS: LiCl stimulated phosphorylation of GSK-3beta and the effect was time-dependent and concentration-dependent to limited extent (P<0.05). Lithium Chloride 9-13 glycogen synthase kinase 3 beta Homo sapiens 44-53 21504119-0 2010 LiCl attenuates thapsigargin-induced tau hyperphosphorylation by inhibiting GSK-3beta in vivo and in vitro. Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 76-85 20093106-6 2010 The inhibitory effect of LRP10 was consistently conserved in HEK293 cells even when GSK3beta phosphorylation was inhibited by incubation with lithium chloride and co-transfection with constitutively active S33Y-mutated beta-catenin. Lithium Chloride 142-158 glycogen synthase kinase 3 beta Homo sapiens 84-92 20090934-7 2010 Inactivation of Gsk3beta activity by inhibitors SB261763 or LiCl upregulated Hsp70. Lithium Chloride 60-64 glycogen synthase kinase 3 beta Homo sapiens 16-24 19887546-7 2009 The GSK-3beta inhibitor, LiCl, partially prevented DHA-induced beta-catenin protein degradation and apoptosis. Lithium Chloride 25-29 glycogen synthase kinase 3 beta Homo sapiens 4-13 20595783-5 2010 We found that pretreatment with genistein or PP2 (general or Src tyrosine kinase inhibitors, respectively) or LiCl [inhibitor of glycogen synthase kinase-3beta (GSK-3beta)] significantly inhibited NA-induced Per1 mRNA expression. Lithium Chloride 110-114 glycogen synthase kinase 3 beta Homo sapiens 129-159 20595783-5 2010 We found that pretreatment with genistein or PP2 (general or Src tyrosine kinase inhibitors, respectively) or LiCl [inhibitor of glycogen synthase kinase-3beta (GSK-3beta)] significantly inhibited NA-induced Per1 mRNA expression. Lithium Chloride 110-114 glycogen synthase kinase 3 beta Homo sapiens 161-170 19706045-8 2009 Stimulating the Wnt/beta-catenin pathway by both Wnt 3a and GSK-3beta inhibitors (LiCl and SB 216763), blocked aspirin-induced apoptosis and protected mitochondrial function, as demonstrated by decreased cytochrome c release and caspase-3 activity. Lithium Chloride 82-86 glycogen synthase kinase 3 beta Homo sapiens 60-69 19823589-9 2009 Interference with GSK3beta activity by siRNA, the specific inhibitor SB216763, or lithium chloride (LiCl) induced tumor cell differentiation. Lithium Chloride 100-104 glycogen synthase kinase 3 beta Homo sapiens 18-26 19652548-5 2009 Moreover, inhibition of GSK3beta with lithium chloride or SB216763 induced T cell proliferation, and the most significant effects were observed in RSLE lymphocytes. Lithium Chloride 38-54 glycogen synthase kinase 3 beta Homo sapiens 24-32 19440036-8 2009 Inhibition of glycogen synthase kinase-3beta by lithium chloride, a highly selective inhibitor, leading to phosphorylation of glycogen synthase kinase-3beta increased Snail expression. Lithium Chloride 48-64 glycogen synthase kinase 3 beta Homo sapiens 14-44 19403565-2 2009 We developed a functional model of xenografted human endometrium to test whether similar mechanisms are operative in the human by using Lithium chloride (LiCl), an inhibitor of GSK3beta. Lithium Chloride 136-152 glycogen synthase kinase 3 beta Homo sapiens 177-185 19403565-2 2009 We developed a functional model of xenografted human endometrium to test whether similar mechanisms are operative in the human by using Lithium chloride (LiCl), an inhibitor of GSK3beta. Lithium Chloride 154-158 glycogen synthase kinase 3 beta Homo sapiens 177-185 19440036-8 2009 Inhibition of glycogen synthase kinase-3beta by lithium chloride, a highly selective inhibitor, leading to phosphorylation of glycogen synthase kinase-3beta increased Snail expression. Lithium Chloride 48-64 glycogen synthase kinase 3 beta Homo sapiens 126-156 19675674-4 2009 However, JNK2-mediated downregulation of beta-catenin was blocked by the proteasome inhibitor MG132 and GSK3beta inhibitor lithium chloride. Lithium Chloride 123-139 glycogen synthase kinase 3 beta Homo sapiens 104-112 19196980-4 2009 Paradoxically, the GSK3beta inhibitors lithium chloride and SB216763 selectively decreased the proliferation of human breast and colorectal cancer cell lines with oncogenic PIK3CA mutations and led to a decrease in the GSK3beta target gene CYCLIN D1. Lithium Chloride 39-55 glycogen synthase kinase 3 beta Homo sapiens 19-27 19416964-8 2009 Importantly, the GSK-3beta inhibitor LiCl prevented hypoxia-induced GCM1 degradation. Lithium Chloride 37-41 glycogen synthase kinase 3 beta Homo sapiens 17-26 19442631-5 2009 Exposure of cells to LiCl, which promotes canonical Wnt signaling by inhibiting GSK-3beta, increased beta-catenin nuclear translocation and up-regulated the transcriptional activity of a canonical Wnt-responsive promoters, suggesting that an endogenous canonical Wnt pathway functions in cementoblasts. Lithium Chloride 21-25 glycogen synthase kinase 3 beta Homo sapiens 80-89 19196980-4 2009 Paradoxically, the GSK3beta inhibitors lithium chloride and SB216763 selectively decreased the proliferation of human breast and colorectal cancer cell lines with oncogenic PIK3CA mutations and led to a decrease in the GSK3beta target gene CYCLIN D1. Lithium Chloride 39-55 glycogen synthase kinase 3 beta Homo sapiens 219-227 19430525-9 2009 Inhibition of GSK-3beta activity using well-characterized inhibitors, LiCl and kenpaullone, and RNA interference, prevented MPP(+)-induced cell death by blocking mitochondrial membrane potential changes and subsequent caspase-9 and -3 activation. Lithium Chloride 70-74 glycogen synthase kinase 3 beta Homo sapiens 14-23 18957842-0 2009 Lithium chloride preconditioning optimizes skeletal myoblast functions for cellular cardiomyoplasty in vitro via glycogen synthase kinase-3beta/beta-catenin signaling. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 113-143 18957842-6 2009 These effects of LiCl were mediated by inactivating glycogen synthase kinase-3beta (GSK-3beta), stabilizing the effector protein beta-catenin and translocating it into the nucleus of SkMs, confirming that LiCl mimics canonical Wnt signaling. Lithium Chloride 17-21 glycogen synthase kinase 3 beta Homo sapiens 52-82 18957842-6 2009 These effects of LiCl were mediated by inactivating glycogen synthase kinase-3beta (GSK-3beta), stabilizing the effector protein beta-catenin and translocating it into the nucleus of SkMs, confirming that LiCl mimics canonical Wnt signaling. Lithium Chloride 17-21 glycogen synthase kinase 3 beta Homo sapiens 84-93 18957842-6 2009 These effects of LiCl were mediated by inactivating glycogen synthase kinase-3beta (GSK-3beta), stabilizing the effector protein beta-catenin and translocating it into the nucleus of SkMs, confirming that LiCl mimics canonical Wnt signaling. Lithium Chloride 205-209 glycogen synthase kinase 3 beta Homo sapiens 52-82 19274078-4 2009 Inactivation of GSK3beta with lithium chloride or the GSK3 inhibitor BIO and GSK3beta knockdown with siRNA repressed cadherin-11 mRNA and protein levels. Lithium Chloride 30-46 glycogen synthase kinase 3 beta Homo sapiens 16-24 19030935-10 2009 Treatment of carcinoid cells with either VPA or SBHA and lithium chloride suppresses the neuroendocrine marker CgA while upregulating Notch1 and inhibiting GSK-3beta. Lithium Chloride 57-73 glycogen synthase kinase 3 beta Homo sapiens 156-165 18615589-2 2008 In the present study, we show that inhibition of glycogen synthase kinase-3beta (GSK-3beta) by lithium chloride (LiCl) elicited a stimulatory effect on DeltaNp63 promoter activity in HEK 293T cells. Lithium Chloride 95-111 glycogen synthase kinase 3 beta Homo sapiens 49-79 18701211-5 2008 In contrast, inactivation of GSK3beta, either by transfection of a dominant-negative mutant inhibitor DN-GSK3beta or with selective inhibitor LiCl, increased cytoplasmic survivin expression, leading to cell-cycle progression and resistance to apoptosis. Lithium Chloride 142-146 glycogen synthase kinase 3 beta Homo sapiens 29-37 18687779-4 2008 Inhibition of glycogen synthase kinase-3beta by lithium chloride or SB415286 also prevented adipogenesis, suggesting that preservation of beta-catenin levels was important to strain inhibition of adipogenesis. Lithium Chloride 48-64 glycogen synthase kinase 3 beta Homo sapiens 14-44 18615589-2 2008 In the present study, we show that inhibition of glycogen synthase kinase-3beta (GSK-3beta) by lithium chloride (LiCl) elicited a stimulatory effect on DeltaNp63 promoter activity in HEK 293T cells. Lithium Chloride 95-111 glycogen synthase kinase 3 beta Homo sapiens 81-90 18615589-2 2008 In the present study, we show that inhibition of glycogen synthase kinase-3beta (GSK-3beta) by lithium chloride (LiCl) elicited a stimulatory effect on DeltaNp63 promoter activity in HEK 293T cells. Lithium Chloride 113-117 glycogen synthase kinase 3 beta Homo sapiens 49-79 18615589-2 2008 In the present study, we show that inhibition of glycogen synthase kinase-3beta (GSK-3beta) by lithium chloride (LiCl) elicited a stimulatory effect on DeltaNp63 promoter activity in HEK 293T cells. Lithium Chloride 113-117 glycogen synthase kinase 3 beta Homo sapiens 81-90 16849547-10 2006 Lithium chloride (LiCl), an inhibitor of glycogen synthase kinase-3beta, increased cytosolic and nuclear beta-catenin level, NOS2 expression, and NO. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 41-71 18972237-7 2008 The authors showed that LiCl mimicked the active canonical Wnt/beta-catenin signaling by glycogen synthase kinase-3beta (GSK-3beta) inactivation and accumulation of the effector protein beta-catenin into the nucleus. Lithium Chloride 24-28 glycogen synthase kinase 3 beta Homo sapiens 89-119 18972237-7 2008 The authors showed that LiCl mimicked the active canonical Wnt/beta-catenin signaling by glycogen synthase kinase-3beta (GSK-3beta) inactivation and accumulation of the effector protein beta-catenin into the nucleus. Lithium Chloride 24-28 glycogen synthase kinase 3 beta Homo sapiens 121-130 18395973-11 2008 The use of the GSK-3beta inhibitor lithium chloride indicated that GSK-3beta partially protects prostate cancer cells from the cytotoxic effects of perifosine. Lithium Chloride 35-51 glycogen synthase kinase 3 beta Homo sapiens 15-24 18395973-11 2008 The use of the GSK-3beta inhibitor lithium chloride indicated that GSK-3beta partially protects prostate cancer cells from the cytotoxic effects of perifosine. Lithium Chloride 35-51 glycogen synthase kinase 3 beta Homo sapiens 67-76 18609681-2 2008 METHODS: Eca-109 cells were treated with lithium chloride, a highly selective inhibitor of glycogen synthase kinase 3beta (GSK-3beta), at different concentrations (2-30 mmol/L) and time points (0, 2, 4, 6 and 24 h). Lithium Chloride 41-57 glycogen synthase kinase 3 beta Homo sapiens 91-121 18609681-2 2008 METHODS: Eca-109 cells were treated with lithium chloride, a highly selective inhibitor of glycogen synthase kinase 3beta (GSK-3beta), at different concentrations (2-30 mmol/L) and time points (0, 2, 4, 6 and 24 h). Lithium Chloride 41-57 glycogen synthase kinase 3 beta Homo sapiens 123-132 18252708-7 2008 Infection of human bronchial smooth muscle cells with pMSCV GSK-3beta-A9, a retroviral vector encoding a constitutively active, nonphosphorylatable GSK-3beta, blocked protein synthesis and alpha-actin expression induced by LiCl, SB216763, and CT-1 but not TGF-beta. Lithium Chloride 223-227 glycogen synthase kinase 3 beta Homo sapiens 60-69 18041091-8 2008 Ser9-phosphorylated GSK3beta or inactivated form would be a key molecule for neuroprotection, insofar as lithium chloride (100 microM) and SB216763 (10 microM), inhibitors of GSK3beta, also induced phosphorylation of GSK3beta at Ser9 and exerted neuroprotection, respectively. Lithium Chloride 105-121 glycogen synthase kinase 3 beta Homo sapiens 20-28 18346908-9 2008 Similarly to TGF-beta1, the GSK-3beta inhibitor lithium chloride (10mM), increased the total levels of beta-catenin and promoted alpha-SMA expression and collagen production. Lithium Chloride 48-64 glycogen synthase kinase 3 beta Homo sapiens 28-37 17666435-6 2007 In this study, we found that caspase-2 activation and the subsequent apoptotic events were abolished by the GSK-3beta inhibitors lithium chloride and SB216763, and by GSK-3beta knockdown using short interfering RNA. Lithium Chloride 129-145 glycogen synthase kinase 3 beta Homo sapiens 108-117 17363508-4 2007 Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A. Lithium Chloride 83-99 glycogen synthase kinase 3 beta Homo sapiens 16-25 17363508-4 2007 Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A. Lithium Chloride 83-99 glycogen synthase kinase 3 beta Homo sapiens 54-63 17363508-4 2007 Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A. Lithium Chloride 101-105 glycogen synthase kinase 3 beta Homo sapiens 16-25 17363508-4 2007 Inactivation of GSK-3beta in TT cells with well-known GSK-3beta inhibitors such as lithium chloride (LiCl) and SB216763 is associated with both growth suppression and a significant decrease in neuroendocrine markers such as human achaete-scute complex-like 1 and chromogranin A. Lithium Chloride 101-105 glycogen synthase kinase 3 beta Homo sapiens 54-63 17145894-7 2006 Adiponectin-mediated suppression of cyclin D1 expression and attenuation of cell proliferation was abrogated by the GSK-3beta inhibitor lithium chloride. Lithium Chloride 136-152 glycogen synthase kinase 3 beta Homo sapiens 116-125 16821070-8 2006 LiCl, a molecule that can inhibit the GSK-3beta activity and down-regulate beta-catenin degradation, could inversely stimulate expression of alpha5 and beta1 integrin. Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 38-47 18318434-9 2008 Suppression of GSK-3beta activity using either a specific inhibitor or lithium chloride significantly reduced tau phosphorylation and partially rescued motor impairment. Lithium Chloride 71-87 glycogen synthase kinase 3 beta Homo sapiens 15-24 18243662-4 2008 Similarly, lithium chloride (LiCl) was found to increase the phosphorylation of GSK-3beta independently of ATM. Lithium Chloride 11-27 glycogen synthase kinase 3 beta Homo sapiens 80-89 18243662-4 2008 Similarly, lithium chloride (LiCl) was found to increase the phosphorylation of GSK-3beta independently of ATM. Lithium Chloride 29-33 glycogen synthase kinase 3 beta Homo sapiens 80-89 18201727-3 2008 Inhibition of GSK3beta activity by LiCl or siRNA technique mimicked insulin action to stimulate ET-1 gene expression. Lithium Chloride 35-39 glycogen synthase kinase 3 beta Homo sapiens 14-22 17671694-7 2007 Lithium chloride, which is a GSK-3beta inhibitor and stimulates pGSK-3beta-ser-9, significantly increased the IC50 of cisplatin and counteracted cisplatin-induced apoptosis of A2780 and CP70 cells. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 29-38 17440966-12 2007 A novel GSK-3-specific inhibitor TDZD-8 and GSK-3beta siRNA also suppressed the expression of these E2F target genes, indicating that LiCl-induced anti-cancer effect was associated with GSK-3beta inhibition. Lithium Chloride 134-138 glycogen synthase kinase 3 beta Homo sapiens 44-53 17440966-12 2007 A novel GSK-3-specific inhibitor TDZD-8 and GSK-3beta siRNA also suppressed the expression of these E2F target genes, indicating that LiCl-induced anti-cancer effect was associated with GSK-3beta inhibition. Lithium Chloride 134-138 glycogen synthase kinase 3 beta Homo sapiens 186-195 16987962-4 2006 In the absence of other treatments, the GSK3beta inhibitors, LiCl or SB216763, induced the formation of stable MTs, but not MTOC reorientation, in starved fibroblasts. Lithium Chloride 61-65 glycogen synthase kinase 3 beta Homo sapiens 40-48 16849547-10 2006 Lithium chloride (LiCl), an inhibitor of glycogen synthase kinase-3beta, increased cytosolic and nuclear beta-catenin level, NOS2 expression, and NO. Lithium Chloride 18-22 glycogen synthase kinase 3 beta Homo sapiens 41-71 15721290-4 2005 LiCl, an inhibitor of glycogen synthase kinase-3beta, also enhanced the Tcf/Lef-dependent transcriptional activity, which was, however, not inhibited by dexamethasone. Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 22-52 16162663-5 2006 We assessed whether pharmacological inhibition of GSK-3beta with lithium chloride (LiCl) was sufficient to stimulate myogenesis. Lithium Chloride 83-87 glycogen synthase kinase 3 beta Homo sapiens 50-59 16322400-7 2005 RESULTS: LiCl dose-dependently inhibited GSK-3beta, stabilized free beta-catenin and inhibited beta-catenin degradation. Lithium Chloride 9-13 glycogen synthase kinase 3 beta Homo sapiens 41-50 16253246-4 2005 Pretreatment of the cells with 10 mM lithium chloride (LiCl), an inhibitor of GSK-3, 1 h before SNP administration inhibits GSK-3beta activation and prevents tau from hyperphosphorylation. Lithium Chloride 37-53 glycogen synthase kinase 3 beta Homo sapiens 124-133 16253246-4 2005 Pretreatment of the cells with 10 mM lithium chloride (LiCl), an inhibitor of GSK-3, 1 h before SNP administration inhibits GSK-3beta activation and prevents tau from hyperphosphorylation. Lithium Chloride 55-59 glycogen synthase kinase 3 beta Homo sapiens 124-133 16153639-5 2005 DIF-1 induced cyclin D1 degradation, but this effect was prevented by treatment with lithium chloride and SB216763, the inhibitors of glycogen synthase kinase-3beta (GSK-3beta). Lithium Chloride 85-101 glycogen synthase kinase 3 beta Homo sapiens 134-164 16153639-5 2005 DIF-1 induced cyclin D1 degradation, but this effect was prevented by treatment with lithium chloride and SB216763, the inhibitors of glycogen synthase kinase-3beta (GSK-3beta). Lithium Chloride 85-101 glycogen synthase kinase 3 beta Homo sapiens 166-175 15878526-5 2005 Lithium chloride treatment, which inhibits GSK3beta activity, reversed these serum starvation effects, which suggests an inverse relationship between Wnt signaling and giant cell formation. Lithium Chloride 0-16 glycogen synthase kinase 3 beta Homo sapiens 43-51 15946992-5 2005 Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release. Lithium Chloride 64-68 glycogen synthase kinase 3 beta Homo sapiens 18-48 15946992-5 2005 Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release. Lithium Chloride 64-68 glycogen synthase kinase 3 beta Homo sapiens 50-59 15946992-5 2005 Inhibition of the glycogen-synthase-kinase-3beta (GSK-3beta) by LiCl prevented this celecoxib-induced translocation, suggesting that phosphorylation of beta-catenin by the GSK-3beta kinase was essential for this release. Lithium Chloride 64-68 glycogen synthase kinase 3 beta Homo sapiens 172-181 15701629-8 2005 Because Wnts inhibit glycogen synthase kinase-3beta, we further determined whether the glycogen synthase kinase-3beta inhibitor LiCl also enhanced cardiac differentiation of CPCs. Lithium Chloride 128-132 glycogen synthase kinase 3 beta Homo sapiens 87-117 16257959-4 2005 Our first finding that treatment of cells with LiCl, a selective inhibitor of another major tau kinase, glycogen synthase kinase-3beta (GSK-3beta), inhibits phosphorylation of Ser-262 of tau led us to investigate the possible involvement of GSK-3beta in MARK2 activation. Lithium Chloride 47-51 glycogen synthase kinase 3 beta Homo sapiens 104-134 15927518-9 2005 In addition, the GSK-3beta inhibitors LiCl and TDZD-8 reduced protein degradation in a similar fashion as IGF-I. Lithium Chloride 38-42 glycogen synthase kinase 3 beta Homo sapiens 17-26 16141410-6 2005 Myocardin-induced ANF transcription and increase in total protein amount were enhanced by GSK3beta blockade (10 mmol/L LiCl), indicating that GSK3beta inhibits myocardin. Lithium Chloride 119-123 glycogen synthase kinase 3 beta Homo sapiens 90-98 16141410-6 2005 Myocardin-induced ANF transcription and increase in total protein amount were enhanced by GSK3beta blockade (10 mmol/L LiCl), indicating that GSK3beta inhibits myocardin. Lithium Chloride 119-123 glycogen synthase kinase 3 beta Homo sapiens 142-150 15845746-7 2005 Inhibition of the GSK-3beta activity in P4-treated uteri by the specific inhibitor, LiCl, reversed the nuclear accumulation of cyclin D1 and in doing so, caused pRB phosphorylation and the induction of downstream genes, proliferating cell nuclear antigen and Ki67. Lithium Chloride 84-88 glycogen synthase kinase 3 beta Homo sapiens 18-27 15668231-6 2005 Inhibition of GSK-3beta activity by LiCl augmented accumulation of beta-catenin and caused induction of versican-Luc activity as well as versican mRNA levels. Lithium Chloride 36-40 glycogen synthase kinase 3 beta Homo sapiens 14-23 15347600-9 2004 Inhibition of GSK3beta by lithium chloride treatment of HeLa cells converted the HIF-1alpha, p16 and p27 loss to levels unchanged by hypoxic exposure. Lithium Chloride 26-42 glycogen synthase kinase 3 beta Homo sapiens 14-22 15952593-5 2005 Pretreatment with ginsenoside Rbl or lithium chloride, a specific inhibitor of GSK-3beta, markedly reduced beta-AP(25-35)-induced tau hyperphosphorylation and the expression of GSK-3beta. Lithium Chloride 37-53 glycogen synthase kinase 3 beta Homo sapiens 79-88 15952593-5 2005 Pretreatment with ginsenoside Rbl or lithium chloride, a specific inhibitor of GSK-3beta, markedly reduced beta-AP(25-35)-induced tau hyperphosphorylation and the expression of GSK-3beta. Lithium Chloride 37-53 glycogen synthase kinase 3 beta Homo sapiens 177-186 15377673-7 2004 Inhibition of GSK-3beta, which is negatively regulated by AKT, using AR-A014418 and lithium chloride completely abolished LY294002-induced NAG-1 expression as well as the NAG-1 promoter activity. Lithium Chloride 84-100 glycogen synthase kinase 3 beta Homo sapiens 14-23 15465828-5 2004 In intact cells, phosphorylation of endogenous Ser(468) of p65 is induced by the PP1/PP2A phosphatase inhibitor calyculin A and this effect is inhibited by the GSK-3beta inhibitor LiCl. Lithium Chloride 180-184 glycogen synthase kinase 3 beta Homo sapiens 160-169 15375508-5 2004 Both estradiol and LiCl enhanced the expression of eNOS mRNA with the phosphorylation of GSK-3beta, but not Akt. Lithium Chloride 19-23 glycogen synthase kinase 3 beta Homo sapiens 89-98 15364539-9 2004 Suspension-induced reporter activation was selectively enhanced by LiCl, which prevented GSK-3beta effects on the simultaneously released beta-catenin. Lithium Chloride 67-71 glycogen synthase kinase 3 beta Homo sapiens 89-98 15247282-8 2004 In addition, the pretreatment with nerve growth factor or lithium chloride, a glycogen synthase kinase-3beta inhibitor, suppressed the cyclin D1 down-regulation caused by MPP(+). Lithium Chloride 58-74 glycogen synthase kinase 3 beta Homo sapiens 78-108 14644163-9 2003 Treatment of HUVEC with LiCl, which inhibits the activity of GSK-3beta and mimicked Wnt-1 signaling, also inhibited the BrdU incorporation in endothelial cells. Lithium Chloride 24-28 glycogen synthase kinase 3 beta Homo sapiens 61-70 15282275-7 2004 Furthermore, lithium chloride, a modulator of glycogen synthase kinase-3beta (GSK-3beta) promoted Schwann cell differentiation, suggesting the involvement of GSK-3beta as a downstream molecule of PI3K-Akt pathways. Lithium Chloride 13-29 glycogen synthase kinase 3 beta Homo sapiens 46-76 15282275-7 2004 Furthermore, lithium chloride, a modulator of glycogen synthase kinase-3beta (GSK-3beta) promoted Schwann cell differentiation, suggesting the involvement of GSK-3beta as a downstream molecule of PI3K-Akt pathways. Lithium Chloride 13-29 glycogen synthase kinase 3 beta Homo sapiens 78-87 15282275-7 2004 Furthermore, lithium chloride, a modulator of glycogen synthase kinase-3beta (GSK-3beta) promoted Schwann cell differentiation, suggesting the involvement of GSK-3beta as a downstream molecule of PI3K-Akt pathways. Lithium Chloride 13-29 glycogen synthase kinase 3 beta Homo sapiens 158-167 14985354-3 2004 Conversely, the glycogen synthase kinase-3 beta inhibitor lithium chloride suppressed the glycogen synthase kinase-3 beta-mediated phosphorylation of the androgen receptor, thereby enabling androgen receptor-driven transcription to occur. Lithium Chloride 58-74 glycogen synthase kinase 3 beta Homo sapiens 16-47 14985354-3 2004 Conversely, the glycogen synthase kinase-3 beta inhibitor lithium chloride suppressed the glycogen synthase kinase-3 beta-mediated phosphorylation of the androgen receptor, thereby enabling androgen receptor-driven transcription to occur. Lithium Chloride 58-74 glycogen synthase kinase 3 beta Homo sapiens 90-121 15178691-5 2004 The suppression of AR transactivation by GSK3 beta was abolished by the GSK3 beta inhibitor lithium chloride. Lithium Chloride 92-108 glycogen synthase kinase 3 beta Homo sapiens 41-50 15178691-5 2004 The suppression of AR transactivation by GSK3 beta was abolished by the GSK3 beta inhibitor lithium chloride. Lithium Chloride 92-108 glycogen synthase kinase 3 beta Homo sapiens 72-81 14988390-3 2004 Pretreatment of prostate cancer cells harboring wild-type or mutant androgen receptor with the GSK-3beta inhibitors, lithium chloride (LiCl), RO318220, or GF109203X, inhibited R1881-stimulated androgen-responsive reporter activity in a dose- and time-dependent manner. Lithium Chloride 117-133 glycogen synthase kinase 3 beta Homo sapiens 95-104 14988390-3 2004 Pretreatment of prostate cancer cells harboring wild-type or mutant androgen receptor with the GSK-3beta inhibitors, lithium chloride (LiCl), RO318220, or GF109203X, inhibited R1881-stimulated androgen-responsive reporter activity in a dose- and time-dependent manner. Lithium Chloride 135-139 glycogen synthase kinase 3 beta Homo sapiens 95-104 21214996-3 2004 The activity of GSK-3beta among those three cell lines was detected by immunoprecipitation and analysed by a radioactive isotope scintillation counter before and after treating with 20 mmol/L LiCl. Lithium Chloride 192-196 glycogen synthase kinase 3 beta Homo sapiens 16-25 21214996-8 2004 (3) After treatment with 20 mmol/L LiCl, the expressive indensity of GSK-3beta of cytoplasm and nucleus was (4 718+-549) and (3 823+-350) IOD in L9981-nm23-H1, (2 030+-155) and (217+-15) IOD in L9981-pLXSN, and (2 164+-151) and (224+-19) IOD in L9981, respectively. Lithium Chloride 35-39 glycogen synthase kinase 3 beta Homo sapiens 69-78 21214996-11 2004 (4) After treatment with 20 mmol/L LiCl, the GSK-3beta activity in cytoplasm and nucleus was (11 099+-1 112) and (3 748+-215) CPM in L9981-nm23-H1, (4 447+-430) and (1067+-159) CPM in L9981, and (4 435+-427) and (909+-156) CPM in L9981-pLXSN, respectively. Lithium Chloride 35-39 glycogen synthase kinase 3 beta Homo sapiens 45-54 21214996-12 2004 The GSK-3beta activity both in cytoplasm and nucleus after treatment with LiCl was remarkably lower than that before treatment in L9981-nm23-H1, L9981-pLXSN and L9981 (P < 0.01 or P < 0.05). Lithium Chloride 74-78 glycogen synthase kinase 3 beta Homo sapiens 4-13 14617795-4 2003 In the presence of lithium chloride (LiCl) or SB216763, the GSK-3beta inhibitors, TRAIL-induced cell death was dramatically enhanced, and the enhanced cell death was an augmented apoptotic response evidenced by increased Annexin V labeling and caspase-3 activation. Lithium Chloride 19-35 glycogen synthase kinase 3 beta Homo sapiens 60-69 14617795-4 2003 In the presence of lithium chloride (LiCl) or SB216763, the GSK-3beta inhibitors, TRAIL-induced cell death was dramatically enhanced, and the enhanced cell death was an augmented apoptotic response evidenced by increased Annexin V labeling and caspase-3 activation. Lithium Chloride 37-41 glycogen synthase kinase 3 beta Homo sapiens 60-69 14550274-7 2003 Inhibition of GSK3beta by LiCl blocks L6 myogenesis, indicating that ILK-mediated inhibition of GSK3beta is not sufficient for differentiation. Lithium Chloride 26-30 glycogen synthase kinase 3 beta Homo sapiens 14-22 14572648-1 2003 Recently, LiCl has been shown to inhibit amyloid beta peptide secretion in association with diminished glycogen synthase kinase beta (GSK3beta) activity. Lithium Chloride 10-14 glycogen synthase kinase 3 beta Homo sapiens 134-142 12943659-3 2003 The catalytic activity was moderately decreased following the inhibition of GSK3beta with LiCl. Lithium Chloride 90-94 glycogen synthase kinase 3 beta Homo sapiens 76-84 12522140-6 2003 DIF-3-induced degradation of cyclin D1 was also prevented by treatment with lithium chloride, an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), suggesting that DIF-3 induced cyclin D1 proteolysis through the activation of GSK-3beta. Lithium Chloride 76-92 glycogen synthase kinase 3 beta Homo sapiens 110-140 12794074-8 2003 Consistent with this, GSK-3 beta inhibits the transcriptional activation of Notch target genes both in vitro and in vivo, whereas lithium chloride treatment or Wnt-1 overexpression that results in GSK-3 beta inhibition leads to the up-regulation of the Hes-1 promoter. Lithium Chloride 130-146 glycogen synthase kinase 3 beta Homo sapiens 197-207 12813129-9 2003 Inhibition of this process by LiCl pointed to participation of GSK-3beta. Lithium Chloride 30-34 glycogen synthase kinase 3 beta Homo sapiens 63-72 12522140-6 2003 DIF-3-induced degradation of cyclin D1 was also prevented by treatment with lithium chloride, an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), suggesting that DIF-3 induced cyclin D1 proteolysis through the activation of GSK-3beta. Lithium Chloride 76-92 glycogen synthase kinase 3 beta Homo sapiens 142-151 12522140-6 2003 DIF-3-induced degradation of cyclin D1 was also prevented by treatment with lithium chloride, an inhibitor of glycogen synthase kinase-3beta (GSK-3beta), suggesting that DIF-3 induced cyclin D1 proteolysis through the activation of GSK-3beta. Lithium Chloride 76-92 glycogen synthase kinase 3 beta Homo sapiens 232-241 11877389-10 2002 The attenuated cell cycle and the reduced c-Myc level were returned to control levels by specific inhibition of GSK3beta using lithium chloride. Lithium Chloride 127-143 glycogen synthase kinase 3 beta Homo sapiens 112-120 12364325-6 2002 Nuclear accumulation of cyclin D1 and cell cycle progression were also observed when LiCl, a known inhibitor of GSK3beta, was added to E(2)-stimulated cells. Lithium Chloride 85-89 glycogen synthase kinase 3 beta Homo sapiens 112-120 12403723-4 2002 Accumulation of beta-catenin by the inhibition of glycogen synthase kinase-3beta with LiCl inhibited chondrogenesis by stabilizing cell-cell adhesion. Lithium Chloride 86-90 glycogen synthase kinase 3 beta Homo sapiens 50-80 12107064-3 2002 Application of IGF-I (250 ng/ml) or LiCl (10 mM) alone (i.e., both inhibit GSK-3beta activity) increased the area of C(2)C(12) myotubes by 80 and 85%, respectively. Lithium Chloride 36-40 glycogen synthase kinase 3 beta Homo sapiens 75-84 12107064-9 2002 LiCl, which inhibits GSK-3beta, removed the block by cGSK-3beta on IGF-I-inducible NFAT-responsive reporter gene activity. Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 21-30 11035789-9 2000 IGF-1 did, however, enhance transcriptional activity in combination with lithium chloride, an inhibitor of glycogen synthase kinase 3 beta, which also stabilizes beta-catenin. Lithium Chloride 73-89 glycogen synthase kinase 3 beta Homo sapiens 107-138 11965545-6 2002 In addition, when GSK-3beta activity was inhibited by lithium chloride, both c-fos promoter activity and protein levels increased. Lithium Chloride 54-70 glycogen synthase kinase 3 beta Homo sapiens 18-27 11402035-6 2001 Similar increases in only CTF levels were seen when cells expressing wild type PS1 were treated with lithium chloride, an inhibitor of GSK-3beta. Lithium Chloride 101-117 glycogen synthase kinase 3 beta Homo sapiens 135-144 11267862-7 2001 LiCl, a potent inhibitor of Glycogen Synthase Kinase 3beta (GSK3beta) activity, abrogated the IL-6-induced inhibition of wild-type beta-catenin. Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 28-58 11267862-7 2001 LiCl, a potent inhibitor of Glycogen Synthase Kinase 3beta (GSK3beta) activity, abrogated the IL-6-induced inhibition of wild-type beta-catenin. Lithium Chloride 0-4 glycogen synthase kinase 3 beta Homo sapiens 60-68 10196136-3 1999 Treatment of COS cells with LiCl, a GSK-3beta inhibitor, and okadaic acid, a protein phosphatase inhibitor, decreased and increased, respectively, the cellular protein level of Axin. Lithium Chloride 28-32 glycogen synthase kinase 3 beta Homo sapiens 36-45